Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Gastrointest Surg ; 26(9): 1853-1862, 2022 09.
Artigo em Inglês | MEDLINE | ID: mdl-35618992

RESUMO

BACKGROUND: The best palliation for double obstruction (duodenal obstruction with biliary obstruction) remains unclear. We aimed to compare outcomes of duodenal stenting (DuS) with gastrojejunostomy (GJ) and identify factors associated with survival time and time to recurrent biliary obstruction (TRBO). METHODS: Patients who underwent DuS or GJ combined with biliary stenting for double obstruction due to unresectable malignancy were retrospectively enrolled. RESULTS: In total, 111 patients were included; 84 underwent DuS, and 27 underwent GJ. The weighted survival time of the DuS group was significantly shorter than that of the GJ group (86 days vs 134 days, P < 0.01). Although the weighted TRBO was not significantly different between the two groups, when limited to patients with distal duodenal obstruction, the weighted TRBO was significantly longer in the DuS group than in the GJ group (207 days vs. 32 days, P < 0.01). GJ for distal duodenal obstruction was identified as the factor with the highest hazard ratio and was associated with a shorter TRBO (hazard ratio 8.5, P < 0.01). CONCLUSIONS: Regarding survival time, GJ should be considered the primary treatment for patients with double obstruction. However, for patients with distal duodenal obstruction, DuS should be considered because GJ may be a risk factor for a shorter TRBO.


Assuntos
Colestase , Obstrução Duodenal , Derivação Gástrica , Stents , Colestase/complicações , Colestase/cirurgia , Obstrução Duodenal/etiologia , Obstrução Duodenal/cirurgia , Derivação Gástrica/efeitos adversos , Humanos , Cuidados Paliativos , Estudos Retrospectivos , Stents/efeitos adversos
2.
Clin J Gastroenterol ; 14(1): 297-303, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32643120

RESUMO

A 72-year-old man with obstructive jaundice, diagnosed with distal biliary carcinoma, underwent pylorus-preserving pancreaticoduodenectomy. The patient was histopathologically and immunohistochemically diagnosed with mixed neuroendocrine non-neuroendocrine neoplasm. Pathological examination revealed that the well-differentiated adenocarcinoma components occupied the superficial portion of the bile duct and the neuroendocrine carcinoma components were located in the deeper portion of the bile duct. Pathological examination showed that a portion of the biliary intraepithelial neoplasia arose from the proximal bile duct and then extended to the gallbladder. The patient was administered tegafur/gimeracil/oteracil as adjuvant chemotherapy, and the lesion did not recur for 6 months postoperatively.


Assuntos
Neoplasias dos Ductos Biliares , Carcinoma in Situ , Idoso , Neoplasias dos Ductos Biliares/cirurgia , Ductos Biliares , Carcinoma in Situ/cirurgia , Ducto Colédoco , Humanos , Masculino , Recidiva Local de Neoplasia
4.
Nihon Shokakibyo Gakkai Zasshi ; 104(12): 1738-44, 2007 Dec.
Artigo em Japonês | MEDLINE | ID: mdl-18057851

RESUMO

A 74-year-old woman was admitted to our hospital to treat her hepatocellular carcinoma (stage IVB) with multiple lung metastases. She was treated with 3 times of hepatic arterial infusion of cisplatin powder (IA-call). After the treatment, liver mass and lung tumors were disappeared and high levels of tumor markers (AFP and PIVKA-II) were markedly decreased. These data revealed that a complete response (CR) was obtained for her. She has still been maintained in CR for 2 years since the first treatment.


Assuntos
Antineoplásicos/administração & dosagem , Carcinoma Hepatocelular/tratamento farmacológico , Carcinoma Hepatocelular/patologia , Cisplatino/administração & dosagem , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/patologia , Neoplasias Pulmonares/secundário , Idoso , Feminino , Humanos , Infusões Intra-Arteriais , Neoplasias Pulmonares/tratamento farmacológico , Pós , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...